相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Improved longitudinal gray and white matter atrophy assessment via application of a 4-dimensional hidden Markov random field model
Michael G. Dwyer et al.
NEUROIMAGE (2014)
Assessing treatment response to interferon-β Is there a role for MRI?
Ruth Dobson et al.
NEUROLOGY (2014)
MRI correlates of disability progression in patients with CIS over 48 months
Tomas Uher et al.
NEUROIMAGE-CLINICAL (2014)
Clinical, MRI, and CSF Markers of Disability Progression in Multiple Sclerosis
Alberto Gajofatto et al.
DISEASE MARKERS (2013)
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event
Bianca Weinstock-Guttman et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2013)
Scoring treatment response in patients with relapsing multiple sclerosis
M. P. Sormani et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes
Angela Vidal-Jordana et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Clinical impact of early brain atrophy in clinically isolated syndromes
F. Perez-Miralles et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis
Antonio Giorgio et al.
NEUROLOGY (2013)
Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study
Dana Horakova et al.
PLOS ONE (2013)
Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis
Robert Zivadinov et al.
RADIOLOGY (2013)
Early predictors of non-response to interferon in multiple sclerosis
D. Horakova et al.
ACTA NEUROLOGICA SCANDINAVICA (2012)
Corpus Callosum Atrophy - A Simple Predictor of Multiple Sclerosis Progression: A Longitudinal 9-Year Study
M. Vaneckova et al.
EUROPEAN NEUROLOGY (2012)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study
Virginia Devonshire et al.
LANCET NEUROLOGY (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study
Tomas Kalincik et al.
PLOS ONE (2012)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
The predictive value of gray matter atrophy in clinically isolated syndromes
M. Calabrese et al.
NEUROLOGY (2011)
Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes
M. Di Filippo et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2010)
Freedom from disease activity in multiple sclerosis
Eva Havrdova et al.
NEUROLOGY (2010)
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
G. Comi et al.
LANCET (2009)
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
Eva Havrdova et al.
LANCET NEUROLOGY (2009)
Measures in the first year of therapy predict the response to interferon β in MS
J. Rio et al.
MULTIPLE SCLEROSIS (2009)
Callosal lesion predicts future attacks after clinically isolated syndrome
N. Jafari et al.
NEUROLOGY (2009)
Disability and T2 MRI lesions:: a 20-year follow-up of patients with relapse onset of multiple sclerosis
L. K. Fisniku et al.
BRAIN (2008)
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
R. Zivadinov et al.
NEUROLOGY (2008)
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
L. Kappos et al.
NEUROLOGY (2006)
Baseline MRI predicts future attacks and disability in clinically isolated syndromes
M. Tintore et al.
NEUROLOGY (2006)
Diagnostic criteria for multiple sclerosis: 2005 Revisions to the McDonald Criteria
CH Polman et al.
ANNALS OF NEUROLOGY (2005)
Clinically isolated syndromes suggestive of multiple sclerosis, part 1: natural history, pathogenesis, diagnosis, and prognosis
D Miller et al.
LANCET NEUROLOGY (2005)
Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study
M Rovaris et al.
BRAIN (2003)
Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time
T Kuhlmann et al.
BRAIN (2002)
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis
PA Brex et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Effect of early interferon treatment on conversion to definite multiple sclerosis:: a randomised study
G Comi et al.
LANCET (2001)
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis.
LD Jacobs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
